Gentamicin remains one of the most effective and commonly used antimicrobials in the armamentarium of clinicians treating pelvic infections. It continues to reliably cover the aerobic gram-negative rods seen within polymicrobial infections. Available in its generic form, it becomes the low-cost drug of choice in these settings. So why mess with success?
Finally, once-daily dosing has the potential to reduce the incidence of nephrotoxicity and ototoxicity associated with the use of aminoglycosides. Uptake of these drugs into the renal tubular cells and endolymph of the ear is more efficient with low sustained concentrations than with high intermittent levels. It also appears that toxicity is delayed in those patients dosed once a day. Given the typical short-term, commando-type use of gentamicin in the treatment of pelvic infections, one could use the agent, expect a response, and discontinue therapy promptly with less concern for toxicity. Measuring aminoglycoside levels is not necessary in most of the patients we treat, allowing for additional cost savings.
Gentamicin use in the combination therapy for pelvic infections has a solid track record of efficacy. Once 
